Oncternal Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$2.88 | -$2.88 | -$2.88 |
| Q2 2024 | 1 | -$3.03 | -$3.03 | -$3.03 |
| Q3 2024 | 1 | -$3.22 | -$3.22 | -$3.22 |
| Q4 2024 | 1 | -$3.47 | -$3.47 | -$3.47 |
| Q1 2025 | 1 | -$2.29 | -$2.29 | -$2.29 |
| Q2 2025 | 1 | -$2.07 | -$2.07 | -$2.07 |
| Q3 2025 | 1 | -$1.89 | -$1.89 | -$1.89 |
| Q4 2025 | 1 | -$1.93 | -$1.93 | -$1.93 |
Oncternal Therapeutics, Inc. Earnings Date And Information
Oncternal Therapeutics, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-2.86 earnings per share for the quarter, topping analysts' consensus estimates of $-3.22 by $0.36. The company had revenue of 0 for the quarter and had revenue of 785,000 for the year. Oncternal Therapeutics, Inc. has generated $-13 earnings per share over the last year ($-13.43 diluted earnings per share) and currently has a price-to-earnings ratio of -0.1. Oncternal Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based on prior year's report dates.
Oncternal Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$3.22 | -$2.86 | 0.36 | $275,000 | $0 |
| 08/08/2024 | Q2 2024 | -$3.03 | -$2.89 | 0.14 | $212,500 | $801,000 |
| 05/09/2024 | Q1 2024 | -$2.88 | -$2.83 | 0.05 | $569,000 | |
| 03/07/2024 | Q4 2023 | -$3.09 | -$3.11 | -0.02 | $297,000 | |
| 11/09/2023 | Q3 2023 | -$3.00 | -$3.35 | -0.35 | $125,000 | $179,000 |
| 08/10/2023 | Q2 2023 | -$3.40 | -$3.05 | 0.35 | $170,833 | $106,000 |
| 05/04/2023 | Q1 2023 | -$4.20 | -$3.92 | 0.28 | $203,000 | |
| 04/28/2023 | Q4 2022 | -$3.85 | $171,000 | |||
| 11/03/2022 | Q3 2022 | -$4.80 | -$0.20 | 4.6 | $325,000 | $382,000 |
| 08/09/2022 | Q2 2022 | -$4.60 | -$0.23 | 4.37 | $459,000 | $191,000 |
| 05/05/2022 | Q1 2022 | -$3.80 | -$0.20 | 3.6 | $746,000 | |
| 03/10/2022 | Q4 2021 | -$5.00 | -$0.16 | 4.84 | $556,000 | |
| 11/04/2021 | Q3 2021 | -$3.20 | -$0.19 | 3.01 | $1.30 M | $2.13 M |
| 08/05/2021 | Q2 2021 | -$2.80 | -$0.16 | 2.64 | $1.09 M | $883,000 |
| 05/06/2021 | Q1 2021 | -$2.00 | -$0.12 | 1.88 | $748,000 | |
| 03/11/2021 | Q4 2020 | -$3.60 | -$0.09 | 3.51 | $1.59 M | |
| 11/04/2020 | Q3 2020 | -$6.00 | -$0.22 | 5.78 | $623,000 | $585,000 |
| 08/06/2020 | Q2 2020 | -$0.34 | $623,000 | |||
| 05/07/2020 | Q1 2020 | -$0.31 | $578,000 | |||
| 03/16/2020 | Q4 2019 | -$0.27 | $736,000 |
Oncternal Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Oncternal Therapeutics, Inc.'s earnings date?
Oncternal Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based off last year's report dates.
-
Did Oncternal Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Oncternal Therapeutics, Inc. (:ONCT) reported $-2.86 earnings per share (EPS) to beat the analysts' consensus estimate of $-3.22 by $0.36.
-
How can I listen to Oncternal Therapeutics, Inc.'s earnings conference call?
The conference call for Oncternal Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Oncternal Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Oncternal Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Oncternal Therapeutics, Inc. generate each year?
Oncternal Therapeutics, Inc. (:ONCT) has a recorded annual revenue of $785,000.
-
How much profit does Oncternal Therapeutics, Inc. generate each year?
Oncternal Therapeutics, Inc. (:ONCT) has a recorded net income of $785,000. Oncternal Therapeutics, Inc. has generated $-13.43 earnings per share over the last four quarters.
-
What is Oncternal Therapeutics, Inc.'s price-to-earnings ratio?
Oncternal Therapeutics, Inc. (:ONCT) has a price-to-earnings ratio of -0.1 and price/earnings-to-growth ratio is -0.02.
